Avastin (Bevacizumab)
Showing 1 - 25 of 2,437
Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas Trial in Miami (SIACI of cetuximab and bevacizumab)
Not yet recruiting
- Glioblastoma Multiforme
- +4 more
- SIACI of cetuximab and bevacizumab
-
Miami, FloridaJackson Memorial Hospital
Jul 14, 2023
Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in New York (Bevacizumab)
Recruiting
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
-
New York, New YorkLenox Hill Brain Tumor Center
Nov 10, 2022
Rectal Cancer, Lung Cancer, Ovarian Cancer Trial in Changchun (Bevacizumab injection, Bevacizumab injection(Avastin))
Completed
- Rectal Cancer
- +4 more
- Bevacizumab injection
- Bevacizumab injection(Avastin)
-
Changchun, Jilin, ChinaAffiliated Hospital of Changchun University of Traditional Chine
Jul 25, 2022
Recurrent Glioblastoma Trial in Miami (Intensity Modulated Proton Therapy (IMPT), Bevacizumab)
Recruiting
- Recurrent Glioblastoma
- Intensity Modulated Proton Therapy (IMPT)
- Bevacizumab
-
Miami, FloridaUniversity of Miami
Sep 30, 2022
Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)
Recruiting
- Colorectal Cancer
- Peritoneal Metastases
- Irinotecan
- +2 more
-
Eindhoven, Netherlands
- +1 more
Aug 15, 2023
Glioblastoma Multiforme, Brain Tumor Trial in New York (Bevacizumab)
Active, not recruiting
- Glioblastoma Multiforme
- Brain Tumor
-
New York, New YorkLenox Hill Brain Tumor Center
Jun 20, 2022
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Trifluridine/Tipiracil Plus Bevacizumab Versus
Completed
- Metastatic Colorectal Adenocarcinoma
-
Changsha, Hunan, ChinaHunan Cancer hospital
May 11, 2023
Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))
Not yet recruiting
- Hepatocellular Carcinoma (HCC)
- Durvalumab
- +2 more
- (no location specified)
Sep 11, 2023
Healthy Trial in Zuidlaren (MYL-1402O, US marketed Avastin(R), EU marketed Avastin(R))
Completed
- Healthy
- MYL-1402O
- +2 more
-
Zuidlaren, NetherlandsPRA Health Sciences - Early Development Services
Mar 9, 2022
Breast Cancer Trial in Oslo, Trondheim (Aromatase Inhibitor, Bevacizumab, Epirubicine)
Completed
- Breast Cancer
- Aromatase Inhibitor
- +6 more
-
Oslo, Norway
- +2 more
Jan 5, 2023
Hepatocellular Carcinoma Trial (Atezolizumab, Bevacizumab)
Not yet recruiting
- Hepatocellular Carcinoma
- (no location specified)
Oct 18, 2023
Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)
Not yet recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +3 more
- (no location specified)
Jun 14, 2023
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial (Atezolizumab Injection, Bevacizumab, Transarterial
Not yet recruiting
- Hepatocellular Carcinoma
- BCLC Stage B Hepatocellular Carcinoma
- Atezolizumab Injection
- +2 more
- (no location specified)
Mar 16, 2023
Retinopathy of Prematurity Trial in Cairo (Intravitreal Bevacizumab)
Completed
- Retinopathy of Prematurity
- Intravitreal Bevacizumab
-
Cairo, EgyptFaculty of Medicine Cairo University
Feb 1, 2023
NSCLC Trial in Russian Federation (Bevacizumab, Paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Bevacizumab
- +2 more
-
Arkhangel'sk, Russian Federation
- +10 more
Dec 8, 2022
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)
Active, not recruiting
- Advanced Cancer
- Temsirolimus
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 11, 2022